{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:48:19Z","timestamp":1785530899171,"version":"3.56.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Febrile neutropenia (FN) is a known side effect of chemotherapy, often requiring hospitalization. Economic burden increases with an FN episode and estimates of cost per episode should be updated from real-world data.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective claims analysis of FN episodes in patients with non-myeloid malignancies from 2014 to 2021 was performed in IQVIA PharMetrics\u00ae Plus database. FN episodes were defined as having same-day claims for neutropenia and fever or infection, plus antibiotic in outpatient settings, following a claim for chemotherapy; index date was defined as the first claim for neutropenia\/fever\/infection. Patients receiving bone marrow\/stem cell transplant and CAR-T therapy were excluded, as were select hematologic malignancies or COVID-19. Healthcare utilization and costs were evaluated and described overall, by episode type (w\/wo hospitalization), index year, malignancy type, NCI comorbidity score, and age group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>7,033 FN episodes were identified from 6,825 patients. Most episodes had a hospitalization (91.2%) and 86% of patients had \u22651 risk factor for FN. Overall, FN episodes had a mean (SD) FN-related cost of $25,176 ($39,943). Episodes with hospitalization had higher average FN-related costs versus those without hospitalization ($26,868 vs $7,738), and costs increased with comorbidity score (NCI=0: $23,095; NCI &gt;0-2: $26,084; NCI \u22652: $26,851).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>FN continues to be associated with significant economic burden, and varied by cancer type, comorbidity burden, and age. In this analysis, most FN episodes were not preceded by GCSF prophylaxis. The results of this study highlight the opportunity to utilize GCSF in appropriate oncology scenarios.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00520-024-08492-5","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T03:34:51Z","timestamp":1716435291000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Chemotherapy-induced febrile neutropenia (FN): healthcare resource utilization (HCRU) and costs in commercially insured patients in the US"],"prefix":"10.1007","volume":"32","author":[{"given":"Jeanine A.","family":"Flanigan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward C.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"issue":"2","key":"8492_CR1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00520-016-3421-x","volume":"25","author":"D Weycker","year":"2017","unstructured":"Weycker D, Li X, Tzivelekis S, Atwood M, Garcia J, Li Y et al (2017) Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor. Support Care Cancer 25(2):439\u2013447","journal-title":"Support Care Cancer"},{"key":"8492_CR2","unstructured":"National Comprehensive Cancer Network Guidelines Panel. NCCN Clinical Practice Guidelines in Oncology: Hematopoietic Growth Factors 2021"},{"issue":"2","key":"8492_CR3","first-page":"128","volume":"29","author":"S Aslam","year":"2023","unstructured":"Aslam S, Li E, Bell E, Lal L, Anderson AJ, Peterson-Brandt J et al (2023) Risk of chemotherapy-induced febrile neutropenia in intermediate-risk regimens: Clinical and economic outcomes of granulocyte colony-stimulating factor prophylaxis. J Manag Care Spec Pharm 29(2):128\u2013138","journal-title":"J Manag Care Spec Pharm"},{"issue":"10","key":"8492_CR4","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/cncr.21847","volume":"106","author":"NM Kuderer","year":"2006","unstructured":"Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 106(10):2258\u20132266","journal-title":"Cancer."},{"key":"8492_CR5","unstructured":"National Comprehensive Cancer Network Guidelines Panel. Panel Discussion 02\/23\/2023. Inclusion of footnote (MGF-1 and MGF-2). 2023"},{"issue":"S1","key":"8492_CR6","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1038\/sj.bjc.6605271","volume":"101","author":"P Trueman","year":"2009","unstructured":"Trueman P (2009) Prophylactic G-CSF in patients with early-stage breast cancer: a health economic review. British J Cancer 101(S1):S15\u2013SS7","journal-title":"British J Cancer"},{"issue":"1","key":"8492_CR7","doi-asserted-by":"publisher","first-page":"64","DOI":"10.6004\/jnccn.2009.0006","volume":"7","author":"J Crawford","year":"2009","unstructured":"Crawford J, Armitage J, Balducci L, Bennett C, Blayney DW, Cataland SR et al (2009) Myeloid growth factors. J Natl Compr Canc Netw 7(1):64\u201383","journal-title":"J Natl Compr Canc Netw"},{"key":"8492_CR8","doi-asserted-by":"publisher","first-page":"4591","DOI":"10.2147\/CMAR.S164201","volume":"10","author":"KB Patel","year":"2018","unstructured":"Patel KB, Arantes LH Jr, Tang WY, Fung S (2018) The role of biosimilars in value-based oncology care. Cancer Manag Res 10:4591\u20134602","journal-title":"Cancer Manag Res"},{"issue":"8","key":"8492_CR9","doi-asserted-by":"publisher","first-page":"e1235","DOI":"10.1200\/OP.20.01047","volume":"17","author":"E Li","year":"2021","unstructured":"Li E, Mezzio DJ, Campbell D, Campbell K, Lyman GH (2021) Primary Prophylaxis With Biosimilar Filgrastim for Patients at Intermediate Risk for Febrile Neutropenia: A Cost-Effectiveness Analysis. JCO Oncol Pract 17(8):e1235\u2013e1e45","journal-title":"JCO Oncol Pract"},{"key":"8492_CR10","unstructured":"National Comprehensive Cancer Network Guidelines Panel. NCCN Clinical Practice Guidelines in Oncology: Prevention and Treatment of Cancer-Related Infections. Version 3.20222022."},{"key":"8492_CR11","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2147\/CEOR.S168298","volume":"10","author":"L Schwartzberg","year":"2018","unstructured":"Schwartzberg L, Lal LS, Balu S, Campbell K, Brekke L, Elliott C et al (2018) Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar. ClinicoEcon Outcomes Res 10:493\u2013500","journal-title":"ClinicoEcon Outcomes Res"},{"issue":"8","key":"8492_CR12","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/oncolo\/oyac074","volume":"27","author":"R Boccia","year":"2022","unstructured":"Boccia R, Glaspy J, Crawford J, Aapro M (2022) Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed? Oncologist 27(8):625\u2013636","journal-title":"Oncologist"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08492-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-024-08492-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08492-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T12:12:38Z","timestamp":1718626358000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-024-08492-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["8492"],"URL":"https:\/\/doi.org\/10.1007\/s00520-024-08492-5","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,23]]},"assertion":[{"value":"4 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As a retrospective study using secondary data, no interventions were made to patients during this study. In compliance with the Health Insurance Portability and Accountability Act (HIPAA), patient data included in the analyses were de-identified; therefore, this study was exempt from Institutional Review Board (IRB) review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Financial interests: M. Yasuda and C. Chen are employees of IQVIA, Inc., which received funding for this study. E. Li and J. Flanigan are employees of Sandoz, Inc., which contracted IQVIA for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"373"}}